Article disscusses DDX3X as a prognostic biomarker in DLBCL.
Home / Resource Library / DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes
Article disscusses DDX3X as a prognostic biomarker in DLBCL.